TTUHSC School of Medicine
HomeSchool of MedicinePharmacology and NeuroscienceFaculty

Pharmacology and Neuroscience

Dr. Lynn T. Frame

Assistant Professor of Pharmacology
Ph.D., University of Arkansas for Medical Sciences

Dr. Lynn Frame currently serves as assistant professor in the Department of Pharmacology, Texas Tech University Health Sciences Center. Dr. Frame held postdoctoral fellowships at the National Center for Toxicological Research NCTR), the University of Arkansas for Health Sciences (UAMS), and The Institute of Environmental and Human Health before receiving her faculty appointment in the Department of Pharmacology at TTUHSC.

Dr. Frame received her Bachelor of Arts in Biology from the University of Virginia, her Master of Science degree in zoology from Virginia Tech University, and her Ph.D. in toxicology from University of Arkansas for Medical Sciences under the direction of Dr. Julian Leakey. For her dissertation, she cloned several human xenobiotic-metabolizing enzymes into human lymphoblastoid cell lines to model human metabolism in vitro. These cell lines are now sold commercially. Her postdoctoral advisors included Fred Kadlubar PhD (NCTR) and Nicholas Lang MD (Oncology, UAMS), who introduced her to the field of cancer molecular epidemiology.

In her research, Dr. Frame attempts to understand toxicological mechanisms and genetic risk factors that are important for chronic low-level toxicant exposures in humans. She uses molecular biological techniques to examine genetic polymorphisms of xenobiotic-metabolizing enzymes in exposed human populations. She also examines differences in expression of certain enzymes that appear to play a role in risk for age-associated diseases, including cancer, Alzheimer’s, and Parkinson’s disease. Animal models are used to study low-level responses to environmental contaminants that may adversely affect neurological health in humans. Currently, she is exploring the significance of dioxin-induced alterations in circadian rhythms.

Representative Publications

Kendall RJ, Anderson TA, Baker RJ, Bens CM, Carr JA, Chiodo LA, Dickerson RL, Dixon KR, Frame LT, Hooper MK, Martin CF, McMurry ST, Patino R, Smith EE, Theodorakis CW (2001) Chapter 30-Ecotoxicology, Casarett and Doule's Toxicology

Frame LT, Ozawa S, Nowell SA, Chou H-C, DeLongchamp RR, Doerge DR, Lang NP, and Kadlubar FF (2000). A simple colorimetric assay for phenotyping the major human thermostable phenol sulfotransferase (SULT1A1) using platelet cytosols. Drug Metabolism and Disposition. 28(9):1063-8

Frame LT, Ambrosone CB, Kadlubar FF, and NP Lang (1998) Host-environment interactions that impact on interindividual variability in susceptibility to human cancer. In: Human variability in response to chemical exposures: measures, modeling and risk assessment (eds: Neuman DA and Kimmel CA) International Life Sciences Institute (ILSI) publication, CRC Press, Boca Raton, FL. pp. 165-204

Miller JD, Settachan D, Frame LT, and Dickerson RL (1999) 2,3,7,8-tetrachlorodibenzo-p-dioxin phase advances the deer mouse (Peromyscus maniculatus) circadian rhythm by altering expression of clock proteins. Organohalogen Compounds 42: 23-28

Frame, LT, Settachan D, and Dickerson RL (1999) 4,4-dichlorodiphenylethylene (4,4-DDE is a 3-methylcholanthrene-type inducer in the deer mouse (Peromyscus maniculatus) but an Aroclor-like inducer in the vole (Microtus ochrogastor). Organohalogen Compounds 43: 57-62

Little JM, Lester R, Kuipers F, Vonk R, Mackenzie PI, Drake RR, Frame L, and Radominska-Pandya A (1999) Variability of human hepatic UDP-glucuronosyltransferase activity. Acta Biochimica Polonica, 46(2):351-63, 1999

Nowell SA, Leakey JEA, Warren, JF, Lang NP, and LT Frame (1998) Identification of enzymes responsible for the metabolism of heme in human platelets. J. Biol. Chem. 1998 273: 33342-46

Bowyer JF, Frame LT, Clausing P, Nagamoto-Combs K, Osterhout CA, Sterling CR, and AW Tank (1998) Long-term effects of amphetamine neurotoxicity on tyrosine hydroxylase mRNA and protein in aged rats. Journal of Pharmacology & Experimental Therapeutics. 286(2):1074-85

For further information contact Dr. Lynn T. Frame